Adjuvants and autoimmunity
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Some adjuvants may exert adverse effects upon injection or, on the other hand, may not trigger a full immunological reaction. The mechanisms underlying adjuvant adverse effects are under renewed scrutiny because of the enormous implications for vaccine development. In the search for new and safer adjuvants, several new adjuvants were developed by pharmaceutical companies utilizing new immunological and chemical innovations. The ability of the immune system to recognize molecules that are broadly shared by pathogens is, in part, due to the presence of special immune receptors called toll-like receptors (TLRs) that are expressed on leukocyte membranes. The very fact that TLR activation leads to adaptive immune responses to foreign entities explains why so many adjuvants used today in vaccinations are developed to mimic TLR ligands. Alongside their supportive role, adjuvants were found to inflict by themselves an illness of autoimmune nature, defined as ‘the adjuvant diseases’. The debatable question of silicone as an adjuvant and connective tissue diseases, as well as the Gulf War syndrome and macrophagic myofaciitis which followed multiple injections of aluminium-based vaccines, are presented here. Owing to the adverse effects exerted by adjuvants, there is no doubt that safer adjuvants need to be developed and incorporated into future vaccines. Other needs in light of new vaccine technologies are adjuvants suitable for use with mucosally delivered vaccines, DNA vaccines, cancer and autoimmunity vaccines. In particular, there is demand for safe and non-toxic adjuvants able to stimulate cellular (Th1) immunity. More adjuvants were approved to date besides alum for human vaccines, including MF59 in some viral vaccines, MPL, AS04, AS01B and AS02A against viral and parasitic infections, virosomes for HBV, HPV and HAV, and cholera toxin for cholera. Perhaps future adjuvants occupying other putative receptors will be employed to bypass the TLR signaling pathway completely in order to circumvent common side effects of adjuvant-activated TLRs such as local inflammation and the general malaise felt because of the costly whole-body immune response to antigen. Lupus (2009) 18, 1217—1225.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene
Poltorak, A., He, X., Smirnova, I., Liu, M.-Y., Huffel, C. V., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., et al. (1998) · Science · doi:10.1126/science.282.5396.2085 · Cited by 7,631
CpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508
Toll-like receptors in innate immunity
Takeda, K. (2004) · International Immunology · doi:10.1093/intimm/dxh186 · Cited by 3,328
T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases
Mempel, T. R., Henrickson, S. E., & von Andrian, U. H. (2004) · Nature · doi:10.1038/nature02238 · Cited by 1,714
Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants
Eisenbarth, S. C., Colegio, O. R., O’Connor, W., Sutterwala, F. S., & Flavell, R. A. (2008) · Nature · doi:10.1038/nature06939 · Cited by 1,542
Akira, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.r300028200 · Cited by 1,479
Inferences, questions and possibilities in Toll-like receptor signalling
Beutler, B. (2004) · Nature · doi:10.1038/nature02761 · Cited by 1,466
Vaccine adjuvants: Current state and future trends
Petrovsky, N., & Aguilar, J. C. (2004) · Immunology & Cell Biology · doi:10.1111/j.0818-9641.2004.01272.x · Cited by 1,005
Kool, M., Soullié, T., van Nimwegen, M., Willart, M. A. M., Muskens, F., Jung, S., Hoogsteden, H. C., Hammad, H., & Lambrecht, B. N. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071087 · Cited by 993
Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes
Bousso, P., & Robey, E. (2003) · Nature Immunology · doi:10.1038/ni928 · Cited by 625
New horizons in adjuvants for vaccine development
Reed, S. G., Bertholet, S., Coler, R. N., & Friede, M. (2009) · Trends in Immunology · doi:10.1016/j.it.2008.09.006 · Cited by 618
Kool, M., Pétrilli, V., De Smedt, T., Rolaz, A., Hammad, H., van Nimwegen, M., Bergen, I. M., Castillo, R., Lambrecht, B. N., & Tschopp, J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.3755 · Cited by 611
Adjuvant-Enhanced Antibody Responses in the Absence of Toll-Like Receptor Signaling
Gavin, A. L., Hoebe, K., Duong, B., Ota, T., Martin, C., Beutler, B., & Nemazee, D. (2006) · Science · doi:10.1126/science.1135299 · Cited by 581
Immunotherapy with a Ragweed–Toll-Like Receptor 9 Agonist Vaccine for Allergic Rhinitis
Creticos, P. S., Schroeder, J. T., Hamilton, R. G., Balcer-Whaley, S. L., Khattignavong, A. P., Lindblad, R., Li, H., Coffman, R., Seyfert, V., Eiden, J. J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052916 · Cited by 562
New horizons in adjuvants for vaccine development
Reed, S. G., Tomai, M., & Gale, M. J. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.08.008 · Cited by 554
Molecular and cellular signatures of human vaccine adjuvants
Mosca, F., Tritto, E., Muzzi, A., Monaci, E., Bagnoli, F., Iavarone, C., O'Hagan, D., Rappuoli, R., & De Gregorio, E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804699105 · Cited by 492
Zimmermann, S., Egeter, O., Hausmann, S., Lipford, G. B., Röcken, M., Wagner, H., & Heeg, K. M. (1998) · PubMed · Cited by 455
Janowsky, E. C., Kupper, L. L., & Hulka, B. S. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003163421105 · Cited by 429
Lipford, G. B., Bauer, M., Blank, C., Reiter, R., Wagner, H., & Heeg, K. (1997) · European Journal of Immunology · doi:10.1002/eji.1830270931 · Cited by 383
Zimmermann, S., Egeter, O., Hausmann, S., Lipford, G. B., Röcken, M., Wagner, H., & Heeg, K. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.8.3627 · Cited by 367
Millan, C. L. B., Weeratna, R., Krieg, A. M., Siegrist, C.-A., & Davis, H. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15553 · Cited by 345
Immunological concepts of vaccine adjuvant activity
Schijns, V. E. (2000) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00120-5 · Cited by 330
Satoh, M., & Reeves, W. H. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.6.2341 · Cited by 320
Monophosphoryl lipid A as an adjuvant. Past experiences and new directions.
Ulrich, J. T., & Myers, K. R. (1995) · PubMed · Cited by 301
Infection, vaccines and other environmental triggers of autoimmunity
Molina, V., & Shoenfeld, Y. (2005) · Autoimmunity · doi:10.1080/08916930500050277 · Cited by 243
Self-citationSatoh, M., Kumar, A., Kanwar, Y. S., & Reeves, W. H. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.24.10934 · Cited by 226
Monophosphoryl Lipid A as an Adjuvant: Past Experiences and New Directions
Ulrich, J. T., & Myers, K. R. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_21 · Cited by 222
Induction of Plasma Cell Tumours in BALB/c Mice with 2,6,10,14-Tetramethylpentadecane (Pristane)
ANDERSON, P. N., & POTTER, M. (1969) · Nature · doi:10.1038/222994a0 · Cited by 192
Kashiwakura, J.-I., Yokoi, H., Saito, H., & Okayama, Y. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.5247 · Cited by 164
Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine
Kuroda, Y., Nacionales, D. C., Akaogi, J., Reeves, W. H., & Satoh, M. (2004) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2004.04.009 · Cited by 105
Nancy, A., & Shoenfeld, Y. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.07.026 · Cited by 97
Self-citationAntibodies to Squalene in Gulf War Syndrome
Asa, P. B., Cao, Y., & Garry, R. F. (2000) · Experimental and Molecular Pathology · doi:10.1006/exmp.1999.2295 · Cited by 96
Ghochikyan, A., Mkrtichyan, M., Petrushina, I., Movsesyan, N., Karapetyan, A., Cribbs, D. H., & Agadjanyan, M. G. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.11.039 · Cited by 88
Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs)
Glück, R. (1999) · Vaccine · doi:10.1016/s0264-410x(98)00440-x · Cited by 61
The Adjuvant Effect in Infection and Autoimmunity
Rose, N. R. (2008) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-007-8049-7 · Cited by 59
Riedl, K., Riedl, R., von Gabain, A., Nagy, E., & Lingnau, K. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.04.029 · Cited by 54
Modulation of adaptive immunity by different adjuvant–antigen combinations in mice lacking Nod2
Moreira, L. O., Smith, A. M., DeFreitas, A. A., Qualls, J. E., Kasmi, K. C. E., & Murray, P. J. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.08.038 · Cited by 44
Cited by
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., Levin, M. J., McElhaney, J. E., Poder, A., Puig-Barberà, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501184 · Cited by 1,454
‘ASIA’ – Autoimmune/inflammatory syndrome induced by adjuvants
Shoenfeld, Y., & Agmon-Levin, N. (2011) · Journal of Autoimmunity · doi:10.1016/j.jaut.2010.07.003 · Cited by 1,010
Self-citationAluminum and Alzheimer's Disease: After a Century of Controversy, Is there a Plausible Link?
Tomljenovic, L. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101494 · Cited by 370
Shaw, C. A., & Tomljenovic, L. (2013) · Immunologic Research · doi:10.1007/s12026-013-8403-1 · Cited by 269
Vaccines, adjuvants and autoimmunity
Guimarães, L. E., Baker, B., Perricone, C., & Shoenfeld, Y. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.08.003 · Cited by 262
Self-citation
Metadata
- Authors
- Israeli, E., Agmon-Levin, N., Blank, M., & Shoenfeld, Y.
- Venue
- Lupus
- Publisher
- SAGE Publications
- Published
- 2009-10-30
- Volume
- 18
- Issue
- 13
- Pages
- 1217-1225
- ISSN
- 0961-2033 (ISSN-L)
- 1477-0962
- OpenAlex
- W2078394827
- Cited by
- 271
- References
- 37
- FWCI
- 9.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.